Michael A. Gillette, M.D., Ph.D.

Broad Institute, Proteomics and Biomarker Discovery
Massachusetts General Hospital
Division of Pulmonary and Critical Care Medicine

Dr. Gillette is an Associate Physician at the Massachusetts General Hospital, an Instructor at the Dana Farber Cancer Institute and Harvard Medical School, and a Senior Research Fellow in Proteomics and Biomarker Discovery at the Broad Institute of MIT and Harvard.  As a practicing pulmonary and critical care physician at the Massachusetts General Hospital, Dr. Gillette has been motivated by the largely phenomenological diagnoses of many disease states, the general lack of “actionable” molecular taxonomies of disease, and the dearth of markers for early disease detection or therapeutic monitoring to develop expertise in the development and application of MS identity- and pattern-based biomarkers.  He leads the Broad Institute efforts in cancer proteomic biomarker discovery, serving as Broad Co-P.I. (with Dr. Steven Carr) on a multi-institutional breast cancer biomarker discovery and verification project jointly supported by the Entertainment Industry Foundation Women’s Cancer Research Fund and Komen for the Cure; heading the proteomic effort on a multi-institutional EDRN-sponsored ovarian cancer program (Steve Skates, MGH, program PI); and maintaining a leadership role in the NCI-sponsored Clinical Proteomics Tumor Analysis Consortium (CPTAC) program that has undertaken to provide deep proteomic and phosphoproteomic annotation of breast, colon and ovarian cancer samples previously genomically characterized as part of The Cancer Genome Atlas.  His biomarker development work extends beyond cancer to infectious diseases of high inter-national health import, including Gates foundation-supported studies in tuberculosis and pediatric febrile illness.  With other Broad colleagues Dr. Gillette has been involved in the development and implementation of all aspects of a coherent biomarker discovery – to – verification pipeline including abundant protein depletion, chroma-tographic fractionation, unbiased discovery MS analysis, AIMS analysis for qualification of candidate biomarkers, and MRM- and SISCAPA-based candidate verification. Dr. Gillette holds an M.D. and Ph.D. (neurophysiology) from Harvard University, Cambridge, MA, and the M.Sc. (Human Biology) and M.A. (Psychology and Philosophy) degrees from Oxford University, Oxford, UK.  He brings a blend of clinical knowledge and current practice, experimental design, mass spectrometry and diverse laboratory skills, and over nine years direct experience to his leadership roles in proteomic biomarker development.